ARTICLE | Company News
CytRx, Merck deal
December 11, 2000 8:00 AM UTC
MRK paid CYTR a $2 million initial fee related to MRK's license of CYTR's TranzFect technology to develop DNA-based vaccines targeted against infectious diseases (see BioCentury, Nov. 13). ...